Establishment of novel treatment for extramammary Paget disease

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08753
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53050:Dermatology-related
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Asai Jun 京都府立医科大学, 医学(系)研究科(研究院), 講師 (50438222)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 乳房街パジェット病 / がんオルガノイド

Outline of Final Research Achievements

CTOSs were successfully prepared from 3 primary lesions and 2 metastatic lymph nodes. Of these, 2 CTOSs (EMPD-3 and EMPD-4) could be maintained and passaged long term ex vivo. Following transplantation of CTOSs to NOD/Scid mice, CTOS-derived xenotumors exhibited ductal formation, indicating that CTOSs retained the original tumor characteristics. Chemo-sensitivity assays revealed that docetaxel significantly inhibited EMPD-3 growth in a dose-dependent manner, whereas EMPD-4 was not clearly inhibited. These findings indicate the heterogeneity of EMPD and potential use of chemosensitivity assays with patient-derived CTOS to select the most effective drugs for each patient.
To our knowledge, this study represents the first establishment of an ex vivo-EMPD disease model involving conventional cell lines. EMPD CTOSs might be useful for developing new therapeutic strategies.

Free Research Field

皮膚腫瘍学

Academic Significance and Societal Importance of the Research Achievements

本研究において、世界で初めて乳房外パジェット病からのがんオルガノイドの分離、継代に成功した。本研究により樹立されたがんオルガノイドを用いることで、乳房外パジェット病の病態解明や新たな治療開発の足がかりとなることが期待される。